Ling Rui Pharmaceutical (600285.SH) subsidiary obtained the drug registration certificate for phenylcycloquine ammonium bromide nasal spray

Zhitongcaijing · 07/01 10:49

Zhitong Financial App News, Lingrui Pharmaceutical (600285.SH) issued an announcement. Recently, the company's subsidiary, Yingu Pharmaceutical Co., Ltd. (“Yingu Pharmaceutical”) received the “Drug Registration Certificate” approved and issued by the State Drug Administration to approve additional indications for the Class 1 innovative drug phenylcycloquine ammonium bromide nasal spray independently developed by Yingu Pharmaceutical to improve the symptoms of runny nose, nasal congestion, itchy nose and sneezing caused by colds.

Phenicloquine ammonium bromide nasal spray has now been approved to increase indications for improving symptoms of runny nose, nasal congestion, itchy nose, and sneezing caused by colds. As a non-hormonal drug, it is the first M receptor antagonist in China to be used as a nasal spray drug for nasal symptoms after a cold. It can effectively reduce patients' symptoms, and has the characteristics of easy use and high safety, which is conducive to further improving product strength.